ChromaDex Corporation
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Frank Louis Jaksch Jr.
- Full Time Employees
- 104
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10900 Wilshire Boulevard Los Angeles CA United States of America 90024
- IPO Date
- Jun 25, 2008
- CIK
- 0001386570
- Website
- chromadex.com
- Similar Companies
- Business
- Niagen Bioscience Inc., formerly ChromaDex Corporation (NASDAQ: NAGE), is a global bioscience company focused on advancing NAD+ science for healthy aging through the discovery, development, and commercialization of proprietary ingredient technologies; it offers Niagen, a patented form of nicotinamide riboside (NR) that boosts NAD+ levels for cellular energy, repair, and metabolic health, supplied as food-grade raw materials to consumer product manufacturers, pharmaceutical-grade formulations to U.S. FDA-registered 503B outsourcing facilities for intravenous (Niagen IV) and injectable products exclusively available at clinics with prescription, and high-bioavailability oral supplements under the Tru Niagen brand sold direct-to-consumer via e-commerce platforms including TRUNIAGEN.com, Amazon, and specialty retailers as well as to healthcare practitioners; the company also provides natural product fine chemicals known as phytochemical reference standards, chemistry and analytical testing services, and related research and development solutions to the dietary supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries worldwide. Founded in 1999 and headquartered in Los Angeles, California, Niagen Bioscience serves health-conscious consumers, researchers, clinicians, and manufacturers across North America, Europe, and other global markets with over 35 human clinical studies, 50 owned and licensed patents, and 300 research collaborations supporting its portfolio. In March 2025, the company rebranded from ChromaDex Corporation to Niagen Bioscience Inc. and changed its NASDAQ ticker from CDXC to NAGE to reflect its leadership in NAD+ innovation; it launched the Niagen+ product line in 2024 including Niagen IV, injections, and a NAD test kit for clinics via partnerships with networks like Wells Pharmacy, Cenegenix, Drip Hydration, REVIVE, Next Health, and Restore Hyper Wellness, marking entry into the $2 billion NAD IV therapy market with superior tolerability and faster NAD+ elevation; recent financials show Q2 2024 net sales of $22.7 million up 12% year-over-year, positive adjusted EBITDA of $1.6 million, and revised 2024 guidance for 10-15% growth amid expansions in e-commerce stability at $13 million quarterly and strategic focus on GLP-1 and Parkinson's applications.
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
ChromaDex to Present at the 37th Annual Roth Conference
ChromaDex Capitalizes On Longevity Boom But Valuation Remains High
ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript
ChromaDex (CDXC) Q4 Earnings and Revenues Surpass Estimates
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
Pick These 4 Stocks With Solid Net Profit Margin to Boost Return
ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
ChromaDex (CDXC) is on the Move, Here's Why the Trend Could be Sustainable
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?
Recent Price Trend in ChromaDex (CDXC) is Your Friend, Here's Why
ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement
What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now?
5 Stocks With Recent Price Strength to Tap Wall Street Rally
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide